首页> 外文期刊>Clinical and experimental hypertension: CEH >Three-year safety and effectiveness of fixed-dose losartan/ hydrochlorothiazide combination therapy in japanese patients with hypertension under clinical setting (PALM-1 extension study)
【24h】

Three-year safety and effectiveness of fixed-dose losartan/ hydrochlorothiazide combination therapy in japanese patients with hypertension under clinical setting (PALM-1 extension study)

机译:临床背景下日本高血压患者固定剂量氯沙坦/氢氯噻嗪联合治疗的三年安全性和有效性(PALM-1扩展研究)

获取原文
获取原文并翻译 | 示例
           

摘要

Concerns about metabolic complications often disturb prolonged use of diuretics in Japan. We investigated 3-year safety and efficacy in Japanese patients with hypertension who were uncontrolled with angiotensin receptor blocker or angiotensin-converting enzyme inhibitor regimens and then switched to losartan (50 mg)/hydrochlorothiazide (12.5 mg; HCTZ) combinations. Blood pressure decreased favorably and maintained a steady state for 3 years (157 ± 16/88 ± 11 mm Hg to 132 ± 13/75 ± 9 mm Hg, P < .0001). Metabolic parameters maintained a limited range of changes after 3 years, and adverse events were markedly decreased after 1-year treatment. The losartan/HCTZ combination minimized diuretic-related adverse effects and thus may be useful for the treatment of Japanese patients with hypertension.
机译:在日本,对代谢并发症的担忧经常会干扰利尿剂的长期使用。我们调查了日本高血压患者的三年安全性和有效性,这些患者未经血管紧张素受体阻滞剂或血管紧张素转化酶抑制剂治疗而无法控制,然后改用氯沙坦(50 mg)/氢氯噻嗪(12.5 mg; HCTZ)组合。血压有利地下降并保持稳定状态3年(157±16/88±11毫米汞柱至132±13/75±9毫米汞柱,P <.0001)。代谢参数在3年后维持有限的变化范围,并且在1年治疗后不良事件显着减少。氯沙坦/ HCTZ的组合最大程度地减少了利尿剂相关的不良反应,因此可用于治疗日本高血压患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号